SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-019654
Filing Date
2023-05-25
Accepted
2023-05-25 08:05:37
Documents
15
Period of Report
2023-05-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K akba-20230524.htm   iXBRL 8-K 45367
2 EX-99.1 exhibit991-eupartnership_f.htm EX-99.1 18749
7 image_0.jpg GRAPHIC 822163
  Complete submission text file 0001628280-23-019654.txt   1342667

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20230524.xsd EX-101.SCH 2256
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20230524_def.xml EX-101.DEF 3781
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20230524_lab.xml EX-101.LAB 27678
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20230524_pre.xml EX-101.PRE 14593
9 EXTRACTED XBRL INSTANCE DOCUMENT akba-20230524_htm.xml XML 11422
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 23956237
SIC: 2834 Pharmaceutical Preparations